Attendance at international biotechnology convention to spur partnership, growth opportunities.
SALT LAKE CITY, May 23, 2022 /PRNewswire-PRWeb/ -- EVŌQ Bio, an early-stage pharmaceutical company developing novel therapeutics against bacterial and fungal pathogens, announced today that it will be attending the BIO International Convention in San Diego, California, from June 13-16, 2022.
During the conference, representatives from EVŌQ Bio will be seeking partnership opportunities for its poly-therapeutic platform, which leverages nanotechnology in the development of antimicrobial applications ranging from pharmaceutical development to fungal/bacterial/biofilm inhibition in implanted or inserted medical devices. EVŌQ Bio's lead asset has a novel mechanism of action halting bacterial metabolic activity.
"As we initiate our FDA path, we're excited to find the right partners to join us in this exciting research and development," said David Nilson, Vice-President of Pharmaceutical Development at EVŌQ Bio. "Our novel therapeutic has the potential to be a first-line, stand-alone broad spectrum treatment against pulmonary bacterial infections including pseudomonas and burkholderia."
The BIO International Conference brings together over 3,000 companies from the world's biotech and pharmaceutical industry, and will be an in-person event for the first time in three years. EVŌQ Bio will be represented by EVŌQ CEO Brian Bertha, EVŌQ Bio VP David Nilson, and EVŌQ Bio Manager of Pharmaceutical Development Dan Garner.
Media Contact
Zach Jacob, EVŌQ Nano, 1 8017559628, [email protected]
SOURCE EVŌQ Nano
Share this article